Sg Americas Securities, LLC Igm Biosciences, Inc. Transaction History

Sg Americas Securities, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Oct 31, 2022	BUY	$15.42 - $27.01 $97,485 - $170,757	6,322 New	6,322 $144,000
Q4 2021 Feb 07, 2022	SELL	$27.59 - $66.39 $173,237 - $416,862	-6,279 Closed	0 $0
Q3 2021 Nov 01, 2021	BUY	$65.76 - $90.65 $328,142 - $452,343	4,990 Added 387.12%	6,279 $413,000
Q2 2021 Aug 12, 2021	SELL	$57.98 - $96.6 $56,994 - $94,957	-983 Reduced 43.27%	1,289 $107,000
Q1 2021 May 13, 2021	SELL	$71.56 - $121.23 $1.08 Million - $1.84 Million	-15,156 Reduced 86.96%	2,272 $174,000
Q4 2020 Feb 04, 2021	SELL	$47.41 - $115.03 $913,021 - $2.22 Million	-19,258 Reduced 52.49%	17,428 $1.54 Million
Q3 2020 Nov 09, 2020	BUY	$43.0 - $84.01 $848,132 - $1.66 Million	19,724 Added 116.28%	36,686 $2.71 Million
Q2 2020 Jul 20, 2020	BUY	$51.3 - $75.21 $773,706 - $1.13 Million	15,082 Added 802.23%	16,962 $1.24 Million
Q1 2020 Apr 30, 2020	BUY	$31.51 - $73.75 $59,238 - $138,650	1,880 New	1,880 $106,000

19.5M

61.3K

36.7K

Ticker IGMS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,969,000
Market Cap $40M
Description
IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non...

Get notified when there are updates to the investment portfolio of Sg Americas Securities, LLC, based on Form 13F filings with the SEC.

Stay updated on Sg Americas Securities, LLC with notifications on news.